This recent article reports that combining venetoclax with full-dose CPX-351 led to high remission rates and enabled most newly diagnosed AML patients, even those with high-risk features, to proceed to stem cell transplant safely.  Read more in our October issue 📖 https://bit.ly/3IV6zDK

🔬 New Podcast!   Dr Anikó Sijs-Szabó & Roger Mulet Lázaro PhD join Dr. Charles de Bock to unpack the challenges of diagnosing & treating acute leukemias of ambiguous lineage #ALAL.  🎧 Listen now on all major platforms & read the full open-access article  https://bit.ly/4oeJo6w #Hematology

This recent paper shows about 10% of recent hematology trials use eligibility criteria that may exclude people with the Duffy null variant. The authors recommend adjusting trial designs to ensure fair inclusion of all patient groups.  Read more in depth here 👉https://bit.ly/4qemD4j

📢 The November issue is now open! Opening the issue: Integrating transcriptomic profiling & machine learning for a clinically actionable prognostic model in infant AML. Read now 👉 https://bit.ly/43SOq0i #AML #MachineLearning #Transcriptomics

🩸 Fresh in HemaSphere Vol. 9(10): B-cell regulation in #WM, ISAKIDS trial, #CAR T-cell therapy burden, ALDH1 in AML, NGS in myeloma, HTLV-1 awareness, & more. Explore cutting-edge hematology! 📰https://bit.ly/4qOjoRm #HemaSphere #BloodCancer #Hematology

HTLV-1 is a silent but serious public health threat in Africa; millions are infected, yet most remain undiagnosed due to limited testing and awareness. Urgent action is needed: improved screening, education, and policy can save lives and stop the spread. 👉https://bit.ly/4qI00oW

This paper shows that ex vivo drug response profiling, combined with molecular analysis, can predict relapse risk and reveal resistance mechanisms in pediatric BCP-ALL, highlighting new targets for precision medicine. Read more here 👉https://bit.ly/3GYLozA #pediatric #hematology

Explore the latest research lurking in our October issue… if you dare! 🎃👻🧟‍♀️http://bit.ly/4haMwh3

Sneak peek of the next podcast episode! Host Dr Charles de Bock chats with Aniko Sijs-Szabo and Roger Mulet-Lázaro,  co-authors of "Transcriptional profiling directs the classification of acute leukemias of ambiguous lineage into AML, B-ALL or T-ALL"

This paper shows that circulating tumor cell counts in newly diagnosed multiple myeloma #MM reflect aggressive disease biology and outperform current transcriptomic markers. The authors suggest integrating CTC data could improve risk stratification and clinical decision-making👉https://bit.ly/4mytPot

Authors show that after initial chemotherapy in pediatric AML, T-cell levels in bone marrow often increase or remain stable, suggesting a possible window for T-cell engager therapy,  They highlight the need for further research on timing and immune recovery.  👉https://bit.ly/3ImTDGg

This recently published paper shows that the female predominance in #PMBCL is linked to Xq24/IL13RA1 defects.  Authors found that unique genetic and epigenetic mechanisms in women drive these changes, which activate oncogenic pathways and define the disease. 👉https://bit.ly/3VI2ohd

🚨REPLAY🚨 In this 2nd part of a 2-part episode, Dr Charles De Bock engages with Prof Dr Petya Apostolova and Dr Jörg Büscher to explore the intricate relationship between metabolism and hematology ➡️https://bit.ly/4o5oE1s Find the referenced Review in full & open access:  https://bit.ly/4kiYh5w

This Editorial highlights the need to expand hospital exemption for  #ATMPs. Authors emphasize the importance of public SoHO establishments in advancing access, affordability, and quality of cell-based therapies, urging policymakers to strengthen regulatory frameworks 👉https://bit.ly/4mwg3Tk

Patient-centered and proportionate safety reporting in clinical trials is an EHA priority. Learn more about EHA's work in this recent HemaSphere Perspective: https://bit.ly/3JbBL1s

#CNS relapse is a concern in high CNS IPI #DLBCL, with CNS prophylaxis considered, though likely ineffective. Systemic relapse is more common and a major cause of death, and authors suggest a focus on systemic treatment., account=@MarekTrnenyDr. 👉https://bit.ly/3JYhiNF

Burnout is highly prevalent among hematology professionals, and it is primarily driven by modifiable structural factors. Time to move ahead !  🚨https://bit.ly/3IDNJR4

📚 Never stop learning with HemaSphere Journal! Access high-quality hematology publications, always #OpenAccess.  Our current issue in progress can always be found here 👉https://bit.ly/3GIlBvj  #OpenAccess #MedicalEducation #CareerDevelopment

Authors report that patients with advanced myeloproliferative neoplasms had poor overall survival.  They also found that combining azacitadine with ruxolitinib may improve outcomes, especially in those without complex TP53 multations. 👉https://bit.ly/480KLjS

🎙️PODCAST REPLAY Host Dr Charles de Bock w/ guests Dr Jörg Büscher & Prof Dr Petya Apostolova discuss the critical role of metabolism in cellular function, particularly in the context of hematology & cancer research. All major podcast platforms 🎧 https://bit.ly/4kiYh5w  📺https://bit.ly/46XCQBY

This recent Perspective highlights the urgent need for timely, equitable, and sustainable access to innovative therapies for large B-cell lymphoma across Europe. Bridging the gap between advancements & real-world patient benefits is essential for improving outcomes👉https://f.mtr.cool/oawlcyeeci

This  EHA Clinical Practice Guideline addresses the critical role of PET-CT imaging in risk stratification, staging, and response assessment, while outlining first-line treatment strategies, including the role of R-CHOP and Pola-R-CHP.  🔥https://f.mtr.cool/dghqpbxugb

ZRSR2 loss causes aberrant splicing in JAK2V617F-driven myeloproliferative neoplasm but is not sufficient to drive disease progression 📰https://f.mtr.cool/xavyesovzb

This paper reports that patients with relapsed or refractory follicular lymphoma treated with varnimcabtagene autoleucel achieved high response rates and durable disease control, with manageable side effects and prolonged CAR T-cell persistence. #R/RFL 🚨https://f.mtr.cool/twlqpmauou

🎧 Inspirational interview from EHA Unplugged with our own Editor in Chief of HemaSphere Prof Jan Cools, who received the EHA 2025 Education & Mentoring Award Prof Cools describes his approach to mentoring, emphasizing the aspects that he finds most crucial in this role 👉https://f.mtr.cool/djtwsgifha

This paper shows that switching elranatamab dosing from weekly to every two weeks did not worsen patient-reported quality of life in relapsed/refractory multiple myeloma. Authors found most symptoms and side effects remained stable for over a year.  👉https://bit.ly/3W3DcBS #MM

Our October issue is now open and live! Find the the most recent clinical, translational and basic #hematology research, always open access and with continuous publication. 🔓 bit.ly/4pZQRaO

This recent paper reports that children w/ T-cell acute lymphoblastic leukemia in the AIEOP-BFM ALL 2009 trial had favorable outcomes Authors highlight that early MRD levels, CNS involvement and prednisone response are important for risk assessment & treatment decisions👉https://f.mtr.cool/prwuxdtqpi

This Editorial highlights how collaboration & mutual support between researchers helped advance understanding of CLL biology, leading to better prognostic tools & therapies Relationships & perseverance are vital in scientific progress, hidden skills not often discussed.👉https://f.mtr.cool/javkjisskd

Our September issue is now complete!   Find the latest #hematology research, always open access 🔓https://f.mtr.cool/rtfwnsvcqm

This study underscores the pronounced elevation of HO-1 levels in pediatric SCD patients, indicating its potential protective role against heme-induced toxicity during childhood. This finding emphasizes the importance of monitoring and managing HO-1 levels in young patients👉https://bit.ly/3IbvCSD

🎙️New Podcast Episode! Join host HemaSphere Scientific Editor Dr Charles de Bock as he chats with Dr Kai Rejeski. The conversation delves into the complexities of CAR-T therapy, particularly focusing on the associated toxicities & the need for a structured grading system. 👉https://bit.ly/46xKjZA

🐾 Happy World Animal Day (Dierendag)! 🐶🐱🐰🐦🐢 Celebrate the love & joy our furry, feathered, and scaly friends bring into our lives! Our pets help us while we review, edit, write & publish, & at least here at HemaSphere often join Zoom calls.  📸 Share your cutest pet photos below.  #Dierendag2025.

Gamma delta (γδ) T cells are pivotal in tumor immunosurveillance & are enriched in epithelial tissues This comprehensive review provides an overview of the rationale for γδ T-cell therapy, ongoing clinical trials, challenges & future role of γδ T-cell-based immune therapies👉https://bit.ly/4lpdYYZ

Arsenic trioxide reprograms bone marrow microenvironment to eliminate #MRD in #AML, an old dog learns new tricks. Read more in our recent issue👉https://f.mtr.cool/syqiavxbqd

These Guidelines on behalf of the European Myeloma Network on VTE prevention & treatment in #MM pts offer evidence-based recommendations. Implementing these guidelines can enhance clinical outcomes and quality of life by reducing morbidity, mortality & treatment interruptions👉https://bit.ly/46kp0uk

Chronic lymphocytic leukemia (CLL) cells reprogram their tumor microenvironment to promote drug resistance and tumor progression. Targeting the AP-1 transcription factor and stromal compartment may offer new treatment strategies. 👉https://f.mtr.cool/ofxyxakidb

Arsenic trioxide reprograms bone marrow microenvironment to eliminate #MRD in #AML, an old dog learns new tricks. Read more in our recent issue👉https://f.mtr.cool/jvybvprmlv

The novel B-CAP regimen has proven to be a feasible and effective first-line treatment for older patients with advanced-stage classic #HL. It results in high response rates, favorable 3-year PFS, and sustained improvement in health-related QOL. 👉https://f.mtr.cool/uondeedlhy

Authors evaluated real-world outcomes of auto-HCT in 130 adult #NKTCL patients across Asia and Europe. Findings suggest that auto-HCT may be a viable treatment option for selected high-risk patients, especially those in complete remission with undetectable EBV-DNA👉https://f.mtr.cool/icmvhpqdkj

Researchers have identified syntenin as a key regulator in the communication between #BMSC and #MM cells.  Authors in this recent article show that targeting syntenin can disrupt this crosstalk, enhancing the effectiveness of bortezomib therapy & potentially improving outcomes👉https://bit.ly/4fCuhAg

Podcast Replay! 🚨 Dr Adrián Mosquera-Orgueira & Dr Juan Carlos Hernández-Boluda, co-authors of "Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis", discuss the findings & challenges w/  Dr Stephen Hibbs  👉

Looking forward to this exciting meeting and to represent @hemasphere-journal.bsky.social in this session!

HemaTopics are HemaSphere publications focusing on 🔥 hematology topics. This week we focus on the latest HemaTopic by Scientific Editor C de Bock, which discusses the discovery of targeting NPM1 as a new therapeutic target for AML immunotherapy.  👉https://f.mtr.cool/dlbgueeraz

📰This exciting Review Article highlights the emerging role of inflammation in the pathogenesis of acute myeloid leukemia (AML). Understanding inflammatory processes in AML could guide therapeutic strategies, especially for elderly patients where outcomes remain poor.👉https://bit.ly/3HbJzzt

Authors of this study present the first humanized MPN xenograft model, demonstrating that PV and ET MSCs can sustain both healthy and MPN-associated hematopoiesis. This model offers valuable insights into the interaction between human BM MSCs and JAK2 V617F mutant clones. 👉

We are excited to announce our new #NDLR2026 Meet-the-Editor session, with Editors-in-Chief, Prof Andrew Roberts, @bloodjournals.hematology.org and Prof @jancools.bsky.social, @hemasphere-journal.bsky.social who will share their invaluable insights on #publishing in high-impact #hematology journals.

🎧 Replay!  Authors of this paper discovered a high-risk subgroup of ped T-LBL, defined by NOTCH1 gene fusions. Prof Roland Kuipers & Dr Jan Loeffen discuss their findings w/ Dr Charles de Bock.  "NOTCH1 fusions in T‐LBL" is on our website & major podcast platforms https://bit.ly/3NhzIHE

📰 This Editorial,  based on a recent HemaSphere article, https://bit.ly/44Kz3bx , highlights the importance of integrating PD-1 blockade into salvage regimens for patients with #RR cHL who have not had prior PD-1 blockade exposure.  👉https://bit.ly/44Kz3bx

🔬 Dive into the latest research with @Hemasphere_EHA! Our open access articles provide ground-breaking insights into #hematology. Stay ahead in your field and collaborate with peers. Our latest issue in progress can always be found here 👉 http://bit.ly/3GIlBvj #Research #OpenAccess